Mounjaro in Hong Kong: Tirzepatide Guide 2026
Mounjaro Has Changed the GLP-1 Conversation
When Mounjaro (tirzepatide) received regulatory approval in Hong Kong, it shifted the weight management conversation in a meaningful way. Until that point, semaglutide — sold as Ozempic and Wegovy — had dominated the GLP-1 space. Mounjaro introduced something different: a dual-receptor mechanism that activates both GLP-1 and GIP pathways, producing weight loss results that, in clinical trials, consistently exceeded those of semaglutide at comparable doses.
The numbers have generated significant interest. In the SURMOUNT-1 trial, participants using tirzepatide 15mg lost an average of 20.9% of their body weight over 72 weeks — roughly double what older first-generation GLP-1 medications produced, and meaningfully higher than semaglutide's 15% average in comparable trials.
This guide covers what Mounjaro is, how it works, whether it's available in Hong Kong, who qualifies, and how REVIV structures its weight management programme for patients considering tirzepatide.
What Is Mounjaro?
Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication developed by Eli Lilly. It was originally developed as a treatment for type 2 diabetes but received dual approval in several markets — including Hong Kong — for both chronic weight management and diabetes.
Tirzepatide is described as a dual GIP/GLP-1 receptor agonist. It works by mimicking two naturally occurring hormones:
GLP-1 (glucagon-like peptide-1) — released by the gut after eating, signals the brain to reduce appetite, slows gastric emptying, and stimulates insulin release
GIP (glucose-dependent insulinotropic polypeptide) — also released after eating, works alongside GLP-1 to regulate insulin and may enhance fat metabolism
By activating both receptors simultaneously, tirzepatide produces a stronger combined effect on appetite suppression, blood sugar regulation, and body composition than single-receptor GLP-1 agonists like semaglutide.
Is Mounjaro Available in Hong Kong?
Yes. Mounjaro (tirzepatide) received regulatory approval in Hong Kong in late 2024, making it the first dual GIP/GLP-1 receptor agonist approved in Hong Kong for both chronic weight management and type 2 diabetes.
This dual approval is significant. Unlike Ozempic, which is approved primarily for diabetes and prescribed off-label for weight management, Mounjaro carries an on-label weight management indication. Clinicians prescribing it for eligible patients who do not have diabetes are doing so within the approved use of the drug.
Mounjaro is a prescription-only medication in Hong Kong and cannot be obtained without a valid prescription from a registered medical practitioner. It is not available over the counter, and patients should be cautious of unregulated online suppliers offering tirzepatide injections without clinical oversight.
Mounjaro vs Ozempic: Key Differences
Both Mounjaro and Ozempic are once-weekly injectable medications used for weight management and diabetes. The key differences are:
Mechanism: Ozempic (semaglutide) activates only the GLP-1 receptor. Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors, producing a stronger combined hormonal signal.
Average weight loss: Clinical trials show tirzepatide produces higher average weight loss — approximately 20–22% of body weight at the highest dose, compared to around 15% for semaglutide at the Wegovy dose. Individual results vary considerably.
Approval status in Hong Kong: Ozempic is approved for type 2 diabetes and used off-label for weight management. Mounjaro has a dual on-label approval for both conditions.
Dose range: Mounjaro is available in 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg doses, titrated upward over months. Ozempic uses 0.5mg, 1mg, and 2mg doses.
Side effect profile: Both have similar gastrointestinal side effects (nausea, constipation, reduced appetite). Mounjaro tends to produce these at a comparable or slightly higher frequency, particularly during dose escalation, though they typically resolve as the body adjusts.
The right choice between the two depends on your health profile, medical history, and weight loss goals. Your doctor will discuss which is more appropriate at your initial consultation.
Who Is Eligible for Mounjaro Treatment?
Eligibility for tirzepatide is determined during a medical consultation and follows Hong Kong Department of Health guidelines. Generally, Mounjaro is appropriate for adults who meet one or more of the following:
BMI of 30 or above
BMI of 27 or abovewith at least one weight-related comorbidity — such as hypertension, dyslipidaemia, type 2 diabetes, insulin resistance, or obstructive sleep apnoea
A history of difficulty achieving or maintaining weight loss through diet and lifestyle changes alone
Mounjaro is not suitable for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It is also contraindicated in pregnancy and breastfeeding, and for patients with a history of pancreatitis. A full medical history review and baseline bloodwork are required before starting treatment.
How REVIV's Mounjaro Programme Works
REVIV runs tirzepatide treatment as part of a structured, medically supervised weight management programme. The focus is on sustainable results with appropriate monitoring — not a standalone prescription service.
The patient journey
Initial doctor consultation — A registered medical practitioner reviews your health history, BMI, relevant bloodwork, and weight loss goals. They'll assess whether Mounjaro or another GLP-1 medication is most appropriate for your profile.
Baseline blood panel — Depending on your medical history, a blood panel may be required before starting. Relevant markers are checked: fasting glucose, HbA1c, liver function, kidney function, lipid profile, and thyroid function. This establishes a baseline where required, and screens for contraindications.
Dose titration — Mounjaro starts at 2.5mg and is titrated upward every four weeks according to tolerability and response. The titration schedule minimises side effects during the adjustment period.
Ongoing monitoring — Regular check-ins with the clinical team track progress, manage side effects, and adjust the programme as needed. Many patients incorporate IV nutritional support alongside the medication — particularly during caloric restriction phases when micronutrient levels may dip.
Lifestyle support — The medication works best alongside dietary guidance and physical activity. REVIV's team provides practical guidance throughout the programme.
New patients begin with a doctor's consultation before any treatment is initiated.
What to Expect: Side Effects and Timeline
Common side effects
The most frequently reported side effects of tirzepatide are gastrointestinal, particularly during the dose escalation period:
Nausea (most common, especially in the first 4–8 weeks)
Decreased appetite
Constipation or changes in bowel habits
Vomiting (less common; usually associated with dose increases)
Mild fatigue or dizziness
These effects are typically mild to moderate and diminish significantly once the body has adapted to the current dose. Eating smaller, lower-fat meals, avoiding eating until full, and staying well hydrated all help. IV hydration and nutritional support can also ease the adjustment period.
Weight loss timeline
Weeks 1–4 (2.5mg): Appetite suppression usually noticeable within the first week. Some nausea, particularly after injection. Most patients experience modest early weight loss.
Months 1–3 (dose escalation phase): Steady weight loss as dose increases. Most patients reach meaningful results (5–10% body weight) in this window.
Months 3–6: Continued weight loss. Clinical trials show most participants reach their peak weight reduction between months 4–8.
Beyond 6 months: Maintenance or plateau phase. Long-term use is typically required to sustain results — discontinuing the medication without durable lifestyle changes usually leads to weight returning.
How Much Does Mounjaro Cost in Hong Kong?
Tirzepatide is generally priced higher than semaglutide in Hong Kong, reflecting both the newer technology and dual-receptor mechanism. As a general guide:
Initial consultation: HK$800
Baseline blood panel: HK$1,200
Monthly medication cost: Starting from HK$4,498, depending on dose
Follow-up consultations: HK$800 per visit
Prices were correct at time of publishing and are subject to change, please contact us for the latest pricing.
REVIV discusses pricing transparently at the initial consultation. There are no hidden costs, and the full programme structure is explained upfront so patients can plan accordingly.
Frequently Asked Questions
Is Mounjaro 'better' than Ozempic?
Clinical trial data consistently shows tirzepatide produces higher average weight loss than semaglutide. But "better" depends on the individual; your health history, any contraindications, tolerance of side effects, and treatment goals all factor into which medication is most appropriate. Your doctor will advise at consultation.
Can I switch from Ozempic to Mounjaro?
Some patients do switch, typically when they have plateaued on semaglutide or want to explore whether tirzepatide produces better results for them. Any switch should be managed by your clinical team with appropriate dose adjustment and monitoring.
How long do I need to take Mounjaro?
Most clinical programmes run 6–12 months or longer. Weight typically returns when the medication is stopped if sustainable lifestyle changes are not in place. Your doctor will help you plan a realistic programme duration and exit strategy.
Can I use IV therapy alongside Mounjaro?
Yes. Many REVIV patients combine tirzepatide with IV nutritional support. The appetite suppression and caloric restriction that come with the medication can reduce micronutrient intake; IV therapy delivers these directly into the bloodstream, bypassing the digestive system. NAD+ and Vitaglow are popular additions during the programme.
Do I need to have diabetes to get Mounjaro in Hong Kong?
No. Mounjaro has an on-label weight management indication in Hong Kong, so it can be prescribed to eligible patients without diabetes who meet the BMI criteria for treatment.
How do I get started?
Book a consultation with REVIV's clinical team. The initial appointment covers your health history, eligibility assessment, and (if appropriate) the recommended treatment pathway and cost structure.
Book a Mounjaro Consultation at REVIV Hong Kong
REVIV's weight management programme is doctor-led, with ongoing clinical oversight throughout your treatment. If you're considering Mounjaro in Hong Kong, the first step is a consultation to determine whether tirzepatide is the right fit for your health profile.
Location: 1st Floor, The Plaza, 21 D'Aguilar Street, Central, Hong Kong
Opening hours: Monday to Sunday, 10:00 AM – 7:00 PM
WhatsApp: +852 9867 9183
Sources
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022.
Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021.
Drucker DJ. GLP-1 Physiology Informs the Pharmacotherapy of Obesity. New England Journal of Medicine, 2022.
Hong Kong Department of Health — Pharmacy and Poisons Ordinance: Prescription Drugs.
The material on this page is provided for informational purposes only and is not medical advice. Always consult your doctor before beginning any therapy programme. All therapies are subject to medical screening and doctor consultation to approve responsible treatment.
